The development of β-lactam/β-lactamase inhibitors seems to be expanding rapidly and promise to be the best short-term strategy against the most recalcitrant Gram-negative pathogens. In this episode, we will discuss the current state of the art in this field.
- How the discovery of β-lactam/β-lactam inhibitors has evolved
- The current state-of-the-art of developing of novel β-lactam/β-lactamase inhibitors
- Robert Bonomo, MD. Professor and Associate Chief of Staff for Academic Affairs; Director Case-VA Center for Antimicrobial Resistance and Epidemiology, Case Western Research University, School of Medicine. Past Editor of AAC
- Pranita Tamma, MD. MH.S. Associate Professor of Pediatrics and Director, Pediatric Antimicrobial Stewardship Program. Johns Hopkins University. Editor of AAC.
Visit aac.asm.org to browse issues and/or submit a manuscript.